Table 1.

miRNA microarray data in the longitudinal study group (MS patients before and at least 12 months after natalizumab therapy)

Upregulated				Downregulated
		Fold change (log2)	P value			Fold change (log2)	P value
1	hsa-miR-18a	0.85	<0.05	1	hsa-miR-411*	−0.72	<0.01
2	hsa-miR-29a	0.76	<0.05	2	hsa-let-7d*	−0.67	<0.01
3	hsa-miR-20b	0.72	<0.05	3	hsa-miR-380*	−0.65	<0.05
4	hsa-miR-103	0.67	<0.01	4	hsa-miR-2117	−0.64	<0.05
5	hsa-miR-532-5p	0.65	<0.05	5	hsa-miR-2116*	−0.40	<0.05
6	hsa-miR-24	0.64	<0.05	6	hsa-miR-1237	−0.30	<0.05
7	hsa-miR-342-3p	0.49	<0.05
8	hsa-miR-7-1*	0.39	<0.05

MS, multiple sclerosis.